Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397121 | 1.00 | HTR2C (0.46) | HTR2CCES2LRRK2HRH3LMNA | |
| SCHEMBL3399714 | 0.92 | HTR2C (0.43) | HTR2CCES2LMNA | |
| SCHEMBL13071979 | 0.88 | HTR2C (0.50) | HTR2CCES2LRRK2HRH3LMNA | |
| SCHEMBL3398930 | 0.88 | HTR2C (0.50) | HTR2CCES2LRRK2HRH3LMNA | |
| SCHEMBL3401794 | 0.85 | NPC1 (0.52) | HTR2CHRH3LMNAL3MBTL3L3MBTL1 | |
| SCHEMBL13071743 | 0.84 | HTR2C (0.60) | HTR2CCES2HRH3LMNAL3MBTL3 | |
| SCHEMBL3405116 | 0.84 | HTR2C (0.60) | HTR2CCES2HRH3LMNAL3MBTL3 | |
| SCHEMBL3402202 | 0.84 | HTR2C (0.44) | HTR2CCES2CYP3A4 | |
| SCHEMBL13310094 | 0.84 | THRA (0.48) | HTR2CLRRK2HRH3LMNAL3MBTL3 | |
| SCHEMBL3400910 | 0.84 | THRA (0.48) | HTR2CLRRK2HRH3LMNAL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | HTR2C 416/4885CES2 1068/4885LRRK2 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.